Stefan Tomic/iStock via Getty Images Listen here or on the go via Apple Podcasts and Spotify Julian Lin runs Best of Breed Growth Stocks. He discusses his high conviction pick: IIPR (0:35). Reasons to be bullish (3:00). IIPR's dividend safety (7:20) 280E taxes and cannabis rescheduling (12:15). Is legalization good for multi-state cannabis operators? (16:30) Risks to REITs (21:00). Red and green flags for management (29:00) How investors should think about valuation (37:05). Transcript Rena Sherbill: ...

TAMPA, Fla., Dec. 31, 2025 (GLOBE NEWSWIRE) -- FLUENT Corp. (CSE: FNT.U) (OTCQB: CNTMF) (“FLUENT” or the “Company”), today announced that it has completed the sale of its Pennsylvania operations to HIVE Holdings, Inc., effective December 31, 2025 for US$12.5 million in cash. The proceeds from the transaction were used to reduce FLUENT’s outstanding debt, which is expected to meaningfully enhance its balance sheet, allowing the Company to further concentrate capital and operational resources on its core grow ...

2026 Marijuana Stocks To Watch As The Sector Begins To ChangeIn 2026, the impact of cannabis rescheduling is expected to be far more visible in marijuana stock performance. Much more than in the initial announcement of cannabis becoming a Class 3 substance. While 2025 seemed to be a transition year, 2026 could mark another pivot point. Specifically, one where improved business operations begin to consistently translate into stronger equity valuations across the sector. Investor sentiment may also shift mean ...

Here’s What To Know About Cannabis Stocks Now That Marijuana Is A Class 3Donald Trump’s recent executive order moving cannabis off Schedule I marks a pivotal moment for the U.S. cannabis sector. While the order does not legalize marijuana at the federal level, rescheduling fundamentally changes how the plant is viewed under federal law. With meaningful implications for operators, investors, and public markets. For the cannabis industry, the most immediate impact is financial. A shift to Schedule III would e ...

Tilray ( TLRY ) announced its entry into US cannabis markets today as Trump signed an EO to reschedule cannabis. The Executive Order directs the federal government to finish the process of reschedulingWelcome to the home of The Cannabis Report. I cover the cannabis sector and other sectors. I am most interested in technical stock analysis, option strategies, small cap strategies, and emerging markets. Feel free to contact me with any questions about publicly traded stocks in the cannabis industry.Analyst’s ...

A leveraged ETF that gives investors exposure to the American cannabis industry looks set to soar following President Donald Trump’s executive order directing the easing of federal restrictions on the psychoactive substance. The AdvisorShares MSOS Daily Leveraged ETF (NYSE:MSOX) , as the name suggests, is a leveraged fund that gives investors exposure to two times the daily total return of the AdvisorShares Pure US Cannabis ETF (NYSE:MSOS) , which is seeing a lot of activity amid this major regulatory shift ...

Core Viewpoint - The issuance of an executive order by President Donald Trump to reschedule cannabis from Schedule I to Schedule III under the U.S. Controlled Substances Act is a significant development for the cannabis industry, enhancing operational economics and enabling expanded medical research [2][3]. Company Summary - LEEF Brands, Inc. is a leading multi-state operator in the cannabis industry, focusing on extraction, manufacturing, and cultivation, with operations in California and New York [6]. - The rescheduling of cannabis will eliminate the 280E tax burden for LEEF, improving cash flow and allowing for more efficient reinvestment in growth initiatives [3]. - The company operates state-of-the-art facilities and believes that the removal of 280E will strengthen balance sheets across the sector, providing more growth capital for expansion [3]. Industry Summary - The reclassification of cannabis is expected to improve access to capital across the cannabis industry, potentially attracting institutional investors and broadening the pool of available lenders [4]. - Improved regulatory clarity may lower the overall cost of capital, creating opportunities for companies to fund growth and scale operations more efficiently [4]. - LEEF is also monitoring developments related to hemp-derived cannabinoids and potential Medicare coverage for CBD products, with a pilot program expected as early as 2026 [4].

Core Viewpoint - The issuance of an executive order by President Donald Trump to reschedule cannabis from Schedule I to Schedule III under the U.S. Controlled Substances Act is a significant development for the cannabis industry, enhancing operational economics and enabling expanded medical research [2][3]. Company Summary - LEEF Brands, Inc. is a leading multi-state operator in the cannabis industry, focusing on extraction, manufacturing, and cultivation, with operations in California and New York [6]. - The rescheduling of cannabis to Schedule III will eliminate the 280E tax burden, improving cash flow and allowing LEEF to reinvest in its workforce, facilities, and long-term growth [3]. - The company operates state-of-the-art extraction and cultivation facilities and believes that the removal of 280E will strengthen balance sheets across the sector, providing more growth capital for expansion [3][4]. Industry Summary - The rescheduling of cannabis is expected to improve access to capital across the cannabis industry, potentially attracting institutional investors and broadening the pool of available lenders [4]. - Improved regulatory clarity may lower the overall cost of capital, creating opportunities for companies to fund growth and scale operations more efficiently [4]. - LEEF is also monitoring developments related to hemp-derived cannabinoids and potential Medicare coverage for certain CBD products, with a pilot program expected as early as 2026 [4].

Schedule III action affirms medical legitimacy and advances a more regulated national cannabis marketTAMPA, Fla., Dec. 18, 2025 (GLOBE NEWSWIRE) -- FLUENT Corp. (CSE: FNT.U) (OTCQB: CNTMF) (“FLUENT” or the “Company”), today applauds the historic federal action directing the rescheduling of cannabis from Schedule I to Schedule III under the Controlled Substances Act, a landmark policy shift that formally recognizes cannabis’s accepted medical use and represents a critical step toward a more rational and regu ...

MARYSVILLE, Ohio, Dec. 18, 2025 (GLOBE NEWSWIRE) -- The Scotts Miracle-Gro Company (NYSE: SMG), the leading marketer of branded consumer lawn and garden products in North America, today expressed support for President Trump’s executive order to reschedule cannabis from a Schedule I to Schedule III drug. “With 39 states already legalizing cannabis in some form, rescheduling to a lower level drug on the federal level has been long overdue,” said Chairman and CEO Jim Hagedorn. “President Trump deserves credit ...